David Rosmarin MD
Company: TUFTS Medical Center
Job title: Associate Professor
Seminars:
2022 & Beyond: What’s the Current & Future State of the JAK Inhibitor Landscape 9:00 am
day: Day One
PANEL DISCUSSION: The JAK Class Black Box Warning: The Implications for the JAK Inhibitor Drug Development Landscape for Dermatology & Beyond 10:00 am
day: Day Two
PANEL DISCUSSION: The JAK Class Black Box Warning: The Implications for the JAK Inhibitor Drug Development Landscape for Dermatology & Beyond 10:00 am
Cataloguing the implications across numerous disciplines the FDA issued JAK black box warning will have just as pharma was beginning to realise the potential the JAK/STAT pathway holds. Evaluating where the community sees the market potential for JAK inhibitors within the pharmaceutical industry despite the warning. Discussing ways in which companies may begin marketing their…Read more
day: Day Two
2022 & Beyond: What’s the Current & Future State of the JAK Inhibitor Landscape 9:00 am
Outlining the successes of the past year in JAK inhibitor drug development Reflecting on the JAK black box warning and the implications this may have on the industry moving forward Highlighting the hot-pockets of innovation where we can expect JAK inhibitors to excelRead more
day: Day One